glp-1 before and after 1 month Semaglutide After: Real Results Month 1 of my GLP-1
Description
For privately insured patients, possible reimbursement depends on the individual tariff, the medical justification, and the specific contract conditions
HM12525A) is also a unimolecular once weekly GLP-1 and glucagon agonist that has been investigated in people with obesity, T2D and MASLD/MASH
For patients deciding between semaglutide and tirzepatide or between weekly injection and daily ODT genetic insight can add another layer of personalization
Patients should be aware that long-term use can be cost-prohibitive
